PF-07248144
PF-07248144 is an experimental small-molecule drug from Pfizer in phase 3 trials for HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.
Overview
PF-07248144 is a small-molecule drug developed by Pfizer. The sponsor describes its target as KAT6 (lysine acetyltransferase, e.g. KAT6A), which OnCo does not yet have a target page for. The sponsor states: PF-07248144 is a KAT6 inhibitor being studied as a single agent and in combination with fulvestrant, letrozole plus palbociclib, PF-07220060 (a CDK4 inhibitor) plus fulvestrant, or vepdegestrant, in HR-positive/HER2-negative breast cancer and other solid tumours. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment), in HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT07062965, plans to enrol 400 participants with primary completion expected 2027-07-22. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"PF-07248144" OR ABSTRACT:"PF-07248144") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PF-07248144, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentPF-08046054
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentENV-501
Shares HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentAglatimagene besadenovec
Shares Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentRC148
Shares HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentBNT324
Shares Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentCetrelimab
Shares Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentVRN110755
Shares Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentGotistobart
Shares Prostate cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.